PhRMA Japan Industry Vision Report

Japan’s rapidly aging population and recent changes to the policy environment have made reforms to the country’s health care system an urgent issue. This vision paper outlines the constructive role innovative biopharmaceutical companies can play to ensure new and innovative medicines continue to be developed and delivered to Japanese patients in a timely manner.

This patient-centric approach is supported by three key pillars: 1) Advancing innovation, 2) Securing patient access to new innovation in a sustainable universal healthcare system, and 3) Ensuring policy decisions are evidence based.


About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:  
www.PhRMA.org
www.Innovation.org 
www.MAT.org
www.Facebook.com/PhRMA 
www.Twitter.com/PhRMA